Search results for " leukocyte"

showing 10 items of 364 documents

Human leukocyte antigen-E mismatch is associated with better hematopoietic stem cell transplantation outcome in acute leukemia patients

2017

The immunomodulatory role of human leukocyte antigen (HLA)-E in hematopoietic stem cell transplantation (HSCT) has not been extensively investigated. To this end, we genotyped 509 10/10 HLA unrelated transplant pairs for HLA-E, in order to study the effect of HLA-E as a natural killer (NK)-alloreactivity mediator on HSCT outcome in an acute leukemia (AL) setting. Overall survival (OS), disease free survival (DFS), relapse incidence (RI) and non-relapse mortality (NRM) were set as endpoints. Analysis of our data revealed a significant correlation between HLA-E mismatch and improved HSCT outcome, as shown by both univariate (53% vs. 38%, P=0.002, 5-year OS) and multivariate (hazard ratio (HR)…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyTransplantation ConditioningAdolescentGenotypemedicine.medical_treatment610Hematopoietic stem cell transplantationHuman leukocyte antigen600 Technik Medizin angewandte Wissenschaften::610 Medizin und GesundheitArticle03 medical and health sciencesYoung Adult0302 clinical medicineCell Therapy & ImmunotherapyInternal medicineMedicineHumansTransplantation Homologousddc:610Potassium Channels Inwardly RectifyingSurvival analysisAllelesAgedBone Marrow TransplantationAcute leukemiabusiness.industryDonor selectionHistocompatibility TestingHazard ratioHistocompatibility Antigens Class IHematopoietic Stem Cell TransplantationHematologyMiddle Agedmedicine.diseasePrognosisSurvival AnalysisTransplantationLeukemiaLeukemia Myeloid Acute030104 developmental biologyTreatment OutcomeImmunologyFemalebusiness030215 immunology
researchProduct

NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival

2019

Abstract Purpose: We investigated the value of tumor-infiltrating NK (TI-NK) cells and HLA class I tumor expression as biomarkers of response to neoadjuvant anti-HER2 antibody–based treatment in breast cancer. Experimental Design: TI-NK cells and HLA-I were determined by IHC in pretreatment tumor biopsies from two cohorts of patients with HER2-positive breast cancer [discovery cohort (n = 42) and validation cohort (n = 71)]. Tumor-infiltrating lymphocytes (TIL) were scored according to international guidelines. Biomarker association with pathologic complete response (pCR) and disease-free survival (DFS) was adjusted for prognostic factors. Gene set variation analysis was used for determinin…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybiologybusiness.industryHuman leukocyte antigenmedicine.diseaseGene expression profiling03 medical and health sciences030104 developmental biology0302 clinical medicineBreast cancerImmune systemOncology030220 oncology & carcinogenesisInternal medicineCohortmedicinebiology.proteinBiomarker (medicine)ImmunohistochemistryAntibodybusinessClinical Cancer Research
researchProduct

Red Blood Cell Distribution Width, Vascular Aging Biomarkers, and Endothelial Progenitor Cells for Predicting Vascular Aging and Diagnosing/Prognosin…

2018

The emerging evidence emphasizes Red blood cell distribution width (RDW) as optimal prognostic biomarker for cardiovascular diseases. However, several clinical biases impede its clinical application. Recent recommendations suggest combining RDW with other biomarkers. Accordingly, we propose evaluating the well-recognized biomarkers of vascular aging (i.e., the leukocyte telomere length and telomerase activity, and reduced levels of endothelial progenitor cells [EPCs]) with RDW, for predicting the risk for vascular aging and onset and prognosis of age-related degenerative arterial diseases, such as sporadic ascending aorta aneurysm (AAA), characterized to have an increased incidence in old p…

0301 basic medicineOncologyErythrocyte IndicesMaleTelomeraseAgingEPCs; RDW; diagnostic and prognostic AAA biomarkers; leukocyte telomere length; risk for vascular aging and sporadic AAA; telomere activityArterial diseaserisk for vascular aging and sporadic AAA0302 clinical medicineRisk FactorsLeukocytesMedicinetelomere activityEndothelial Progenitor CellsAged 80 and overMiddle AgedTelomerePrognosisAortic AneurysmC-Reactive Proteincardiovascular systemBiomarker (medicine)Vascular agingFemaleAdultmedicine.medical_specialtydiagnostic and prognostic AAA biomarkersleukocyte telomere length03 medical and health sciencesYoung AdultInternal medicinemedicine.arterySettore MED/05 - Patologia ClinicaRDWHumansVascular DiseasesProgenitor cellAgedAortabusiness.industrySettore MED/23 - Chirurgia CardiacaRed blood cell distribution widthEPCTelomere030104 developmental biologyCase-Control StudiesEPCsGeriatrics and Gerontologybusinessdiagnostic and prognostic AAA biomarker030217 neurology & neurosurgeryBiomarkersRejuvenation research
researchProduct

Myositis/myasthenia after pembrolizumab in a bladder cancer patient with an autoimmunity-associated HLA: Immune–biological evaluation and case report

2021

Pembrolizumab (mAb to PD-1) has been recently approved for the therapy of pretreated urothelial cancer. Despite the efficacy, it is often accompanied by unpredictable and sometime severe immune-related (ir) adverse events (AEs). Here, we report the clinical and immune–biological characterization of a patient with a metastatic bladder cancer who developed myositis signs (M) and a myasthenia-like syndrome (MLS) during treatment with pembrolizumab. The patient presented an autoimmunity-associated HLA haplotype (HLA-A*02/HLA-B*08/HLA-C*07/HLA-DRB1*03) and experienced an increase in activated CD8 T-cells along the treatment. The symptomatology regressed after pembrolizumab discontinuation and a …

0301 basic medicineOncologyMaleCase ReportAutoimmunityPembrolizumabPD1-checkpoint inhibitorsmedicine.disease_causeAutoimmunity0302 clinical medicineAntineoplastic Agents ImmunologicalBiology (General)HLA AntigenMyositiPD1-checkpoint inhibitorSpectroscopyMyositisGeneral MedicineComputer Science ApplicationsMyasthenia GraviChemistryPyridostigmineurothelial cancer030220 oncology & carcinogenesisUrinary Bladder NeoplasmClass-I/II HLAMyastheniamedicine.drugHumanmedicine.medical_specialtyQH301-705.5PrognosiHuman leukocyte antigenAntibodies Monoclonal HumanizedCatalysisInorganic Chemistry03 medical and health sciencesInternal medicinemedicinePhysical and Theoretical ChemistryAdverse effectMolecular BiologyQD1-999Agedbusiness.industryOrganic ChemistryCancermedicine.diseaseDiscontinuation030104 developmental biologybusiness
researchProduct

HLA-E-Restricted CD8+ T Lymphocytes Efficiently Control Mycobacterium tuberculosis and HIV-1 Co-Infection

2020

We investigated the contribution of human leukocyte antigen A2 (HLA-A2) and HLA-E-restricted CD8+ T cells in patients with Mycobacterium tuberculosis and human immunodeficiency virus 1 (HIV-1) coinfection. HIV-1 downregulates HLA-A, -B, and -C molecules in infected cells, thus influencing recognition by HLA class I-restricted CD8+ T cells but not by HLA-E-restricted CD8+ T cells, owing to the inability of the virus to downmodulate their expression. Therefore, antigen-specific HLA-E-restricted CD8+ T cells could play a protective role in Mycobacterium tuberculosis and HIV-1 coinfection. HLA-E- and HLA-A2-restricted Mycobacterium tuberculosis-specific CD8+ T cells were tested in vitro for cyt…

0301 basic medicinePulmonary and Respiratory MedicineAdultMaleTetramersTuberculosisHLA-EClinical BiochemistryT lymphocytesDown-RegulationHIV InfectionsHuman leukocyte antigenCD8-Positive T-Lymphocytes+Lymphocyte ActivationMycobacterium tuberculosis03 medical and health sciences0302 clinical medicineAntigenHLA-A2 AntigenmedicineCytotoxic T cellHumansTuberculosisLymphocyte CountMolecular BiologyAntigens BacterialbiologyCoinfectionHistocompatibility Antigens Class ICD8 T lymphocytes HLA-E Mycobacterium tuberculosis HIV tetramersCell BiologyCD8Mycobacterium tuberculosisMiddle Agedbiology.organism_classificationmedicine.diseaseVirology030104 developmental biology030228 respiratory systemCoinfectionHIV-1FemaleCD8Mycobacterium
researchProduct

Diagnostic and Prognostic Relevance of Red Blood Cell Distribution Width for Vascular Aging and Cardiovascular Diseases.

2019

Evidence suggests association of red blood cell distribution width (RDW) with cardiovascular diseases (CVDs). On the contrary, we underline that the sole RDW values cannot represent a valid CVD biomarker. High RDW values are expression of biological effects of a lot of both endogenous and exogenous factors (i.e., age, sex, genetic background, inflammation, hormones, drugs, diet, exercise, hematological analyzers, and ranges of values), modulating the biology and physiology of erythrocytes. Thus, the singular monitoring of RDW cannot be used to predict cardiovascular disorders. Accordingly, we have reviewed the evidence for potential relationship of RDW values with alterations in the cardiov…

0301 basic medicineSenescenceErythrocyte Indicescirculating endothelial progenitor cells and nucleated red blood cellAgingleukocyte telomere lengthsInflammationDiseaseBioinformaticsEpigenesis Geneticleukocyte telomere length03 medical and health sciencesCVDs; RDW; circulating endothelial progenitor cells and nucleated red blood cells; leukocyte telomere lengths; vascular aging; Aging; Biomarkers; Cardiovascular Diseases; Epigenesis Genetic; Humans; Prognosis; Erythrocyte Indices0302 clinical medicineGeneticmedicineRDW; CVDs; vascular ageing; leukocyte telomere lengths; circulating endothelial progenitor cells and nucleated red blood cells.Settore MED/05 - Patologia ClinicaRDWHumansCVDsProgenitor cellvascular ageingbusiness.industryNucleated Red Blood CellRed blood cell distribution widthCVDPrognosisSettore MED/23030104 developmental biologyvascular agingCardiovascular DiseasesBiomarker (medicine)Geriatrics and Gerontologymedicine.symptombusiness030217 neurology & neurosurgerycirculating endothelial progenitor cells and nucleated red blood cellsBiomarkersHormoneEpigenesisRejuvenation research
researchProduct

No diagnostic utility of antibody patterns against Klebsiella pneumoniae capsular serotypes in patients with axial spondyloarthritis vs. patients wit…

2017

OBJECTIVES: To investigate whether antibody response patterns against Klebsiella pneumoniae capsular serotypes can discriminate patients with axial spondyloarthritis (axSpA) from patients with non-specific low back pain (LBP).METHOD: Immunoglobulin (Ig)G and IgA antibodies against K. pneumoniae capsular serotypes K2, K26, K36, and K50 were measured, and antibody seropositivity compared between groups and analysed for patient correlation in five different groups: (a) 96 patients fulfilling the Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axSpA; (b) 38 patients with either a positive magnetic resonance imaging (MRI) scan as defined by ASAS or a posi…

0301 basic medicineSerotypeMaleCross-sectional studyKlebsiella pneumoniaeDenmarkGastroenterology0302 clinical medicineImmunology and AllergyHLA-B27 Antigenbiologymedicine.diagnostic_testGeneral MedicineLow back painAntibodies BacterialMagnetic Resonance ImagingKlebsiella pneumoniaeC-Reactive ProteinFemaleAntibodymedicine.symptomAdultmedicine.medical_specialtyAdolescentImmunologyHuman leukocyte antigenSerogroup03 medical and health sciencesYoung AdultRheumatologyInternal medicineJournal ArticlemedicineHumansSpondylitis AnkylosingLow back painSacroiliitisBacterial Capsules030203 arthritis & rheumatologyAnkylosing spondylitisbusiness.industryta1182Magnetic resonance imagingaxial spondyloarthritismedicine.diseasebiology.organism_classificationantibody response patternsImmunoglobulin A030104 developmental biologyCase-Control StudiesImmunoglobulin GImmunologybiology.proteinSpondylarthropathiesbusinessLow Back Pain
researchProduct

HLA and killer cell immunoglobulin-like receptor (KIRs) genotyping in patients with acute viral encephalitis

2018

// Antonino Tuttolomondo 1 , Claudia Colomba 2 , Danilo Di Bona 6 , Alessandra Casuccio 4 , Domenico Di Raimondo 1 , Giuseppe Clemente 1 , Valentina Arnao 5 , Rosaria Pecoraro 1 , Paolo Ragonese 5 , Anna Aiello 3 , Giulia Accardi 3 , Rosario Maugeri 5 , Carlo Maida 1 , Irene Simonetta 1 , Vittoriano Della Corte 1 , Domenico Gerardo Iacopino 5 , Calogero Caruso 3 , Antonio Cascio 2 and Antonio Pinto 1 on behalf of KIRIIND (KIR Infectious and Inflammatory Diseases) Collaborative Group 1 U.O.C di Medicina Interna con Stroke Care, Dipartimento Biomedico di Medicina Interna e Specialistica (Di.Bi.M.I.S), Universita degli Studi di Palermo, Palermo, Italy 2 U.O.C di Malattie Infettive, Dipartiment…

0301 basic medicineSettore MED/09 - Medicina InternaencephalitisKiller-cell immunoglobulin-like receptorHuman leukocyte antigenAcute viral encephalitis03 medical and health sciences0302 clinical medicineEncephalitimedicineIn patientGenotypingSettore MED/04 - Patologia Generalebusiness.industryHaplotypemedicine.diseaseVirologyKIRHLA030104 developmental biologyEncephalitis; HLA; KIRs; OncologyOncologybusinessKIR3DL1KIRs030217 neurology & neurosurgeryEncephalitisResearch Paper
researchProduct

Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma.

2018

Abstract The quest for tumor-associated antigens (TAA) and neoantigens is a major focus of cancer immunotherapy. Here, we combine a neoantigen prediction pipeline and human leukocyte antigen (HLA) peptidomics to identify TAAs and neoantigens in 16 tumors derived from seven patients with melanoma and characterize their interactions with their tumor-infiltrating lymphocytes (TIL). Our investigation of the antigenic and T-cell landscapes encompassing the TAA and neoantigen signatures, their immune reactivity, and their corresponding T-cell identities provides the first comprehensive analysis of cancer cell T-cell cosignatures, allowing us to discover remarkable antigenic and TIL similarities b…

0301 basic medicineT cellmedicine.medical_treatmentT-LymphocytesAntigen presentationHuman leukocyte antigenMice SCIDBiologyArticle03 medical and health sciencesMiceImmune systemLymphocytes Tumor-InfiltratingAntigenCancer immunotherapyAntigens NeoplasmMice Inbred NODmedicineTumor Cells CulturedAnimalsHumansMelanomaAntigen Presentationintegumentary systemMelanomaHistocompatibility Antigens Class Imedicine.diseaseXenograft Model Antitumor Assays3. Good health030104 developmental biologymedicine.anatomical_structureOncologyCancer cellCancer researchCancer discovery
researchProduct

Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery

2020

Successful outcome of immune checkpoint blockade in patients with solid cancers is in part associated with a high tumor mutational burden (TMB) and the recognition of private neoantigens by T-cells. The quality and quantity of target recognition is determined by the repertoire of ‘neoepitope’-specific T-cell receptors (TCRs) in tumor-infiltrating lymphocytes (TIL), or peripheral T-cells. Interferon gamma (IFN-γ), produced by T-cells and other immune cells, is essential for controlling proliferation of transformed cells, induction of apoptosis and enhancing human leukocyte antigen (HLA) expression, thereby increasing immunogenicity of cancer cells. TCR αβ-dependent therapies should account f…

0301 basic medicineT-Lymphocytesmedicine.medical_treatmentprecision medicineImmunologyEpitopes T-LymphocyteReviewHuman leukocyte antigenBiologyMajor histocompatibility complexCancer Vaccines03 medical and health sciencesLymphocytes Tumor-Infiltrating0302 clinical medicineImmune systemAntigenAntigens NeoplasmantigensNeoplasmsmedicineAnimalsHumansImmunology and AllergyT-cell receptorTumor microenvironmentneoepitopesWhole Genome SequencingT-cellsT-cell receptorComputational BiologyImmunotherapyTILRC581-607vaccinationImmune checkpoint030104 developmental biology030220 oncology & carcinogenesisCancer researchbiology.proteinimmunotherapyImmunologic diseases. AllergyFrontiers in Immunology
researchProduct